Hologic, Inc. (NASDAQ:HOLX) Stake Boosted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,971,617 shares of the medical equipment provider’s stock after acquiring an additional 16,057 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Hologic were worth $160,608,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Hologic by 0.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 354,727 shares of the medical equipment provider’s stock worth $28,896,000 after purchasing an additional 945 shares in the last quarter. FORA Capital LLC increased its holdings in Hologic by 13.5% in the third quarter. FORA Capital LLC now owns 10,730 shares of the medical equipment provider’s stock worth $874,000 after buying an additional 1,277 shares during the last quarter. Townsquare Capital LLC raised its position in Hologic by 8.7% during the third quarter. Townsquare Capital LLC now owns 34,321 shares of the medical equipment provider’s stock valued at $2,796,000 after acquiring an additional 2,755 shares in the last quarter. Brooklyn Investment Group acquired a new stake in Hologic in the third quarter valued at approximately $80,000. Finally, Prospector Partners LLC grew its position in Hologic by 3.2% in the third quarter. Prospector Partners LLC now owns 132,705 shares of the medical equipment provider’s stock worth $10,810,000 after acquiring an additional 4,068 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the topic of several analyst reports. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Tuesday, October 15th. JPMorgan Chase & Co. raised their price objective on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Royal Bank of Canada upped their target price on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. UBS Group increased their price target on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $89.91.

Hologic Stock Performance

NASDAQ:HOLX opened at $79.50 on Friday. The firm’s 50-day moving average is $80.18 and its 200-day moving average is $78.45. The company has a market cap of $18.47 billion, a price-to-earnings ratio of 23.87, a PEG ratio of 2.50 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a 52-week low of $67.59 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same period in the previous year, the company posted $0.89 earnings per share. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. Equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.